Metastatic Breast Cancer Recurrence after Bone Fractures

被引:2
作者
Obi, Nadia [1 ]
Werner, Stefan [2 ,3 ]
Thelen, Frank [4 ]
Becher, Heiko [1 ]
Pantel, Klaus [2 ]
机构
[1] Univ Med Ctr Hamburg Eppendorf, Inst Med Biometry & Epidemiol, Martinistr 52, D-20246 Hamburg, Germany
[2] Univ Med Ctr Hamburg Eppendorf, Inst Tumor Biol, Martinistr 52, D-20246 Hamburg, Germany
[3] Univ Canc Ctr Hamburg, Mildred Scheel Nachwuchszentrum HaTRiCs4, D-20246 Hamburg, Germany
[4] Techniker Krankenkasse, Analyt & Insights, Bramfelder Str 140, D-22305 Hamburg, Germany
基金
欧洲研究理事会;
关键词
metastasis; breast cancer; risk of relapse; bone fractures; administrative data; TUMOR-CELLS; MARROW; STAGE; SURVIVAL;
D O I
10.3390/cancers14030601
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Bone fractures bear potential risk to promote metastatic relapse in breast cancer. We conducted a population-based cohort study of 84,300 breast cancer patients diagnosed between January 2015 and November 2019. Bone fracture after breast cancer diagnosis was associated with an increased metastasis risk. Fractures may pose an increased risk to developing metastasis. Potential clinical implications for cancer patients are in support of fall prevention programs. Experimental studies suggest that bone fractures result in the release of cytokines and cells that might promote metastasis. Obtaining observational data on bone fractures after breast cancer diagnoses related to distant breast cancer recurrence could help to provide first epidemiological evidence for a metastasis-promoting effect of bone fractures. We used data from the largest German statutory health insurance fund (Techniker Krankenkasse, Hamburg, Germany) in a population-based cohort study of breast cancer patients with ICD-10 C50 codes documented between January 2015 and November 2019. The risk of metastasis overall, regional, distant non-bone or bone metastasis related to a fracture was modeled by an adjusted discrete time-to-event analysis with time-dependent exposure. Of 154,000 breast cancer patients, 84,300 fulfilled the inclusion criteria and had a follow-up time of more than half a year. During follow-up, fractures were diagnosed in 13,579 (16.1%) patients. Metastases occurred in 7047 (8.4%) patients; thereof 1544 had affected regional lymph nodes only and 5503 distant metastases. Fractures demonstrated a statistically significant association with subsequent metastasis overall (adjusted HR 1.12, 95% CI 1.04, 1.20). The highest risk for metastasis was observed in patients with subsequent bone metastasis (adjusted HR 1.18, 95% CI 1.05, 1.34), followed by distant non-bone metastasis (adjusted HR 1.16, 95% CI 1.07, 1.26) and lymph node metastasis (adjusted HR 1.08, 95% CI 0.97, 1.21).
引用
收藏
页数:10
相关论文
共 38 条
  • [1] Estimation of Disease Incidence in Claims Data Dependent on the Length of Follow-Up: A Methodological Approach
    Abbas, Sascha
    Ihle, Peter
    Koester, Ingrid
    Schubert, Ingrid
    [J]. HEALTH SERVICES RESEARCH, 2012, 47 (02) : 746 - 755
  • [2] The Cancer Cell Dissemination Machinery as an Immunosuppressive Niche: A New Obstacle Towards the Era of Cancer Immunotherapy
    Asiry, Saeed
    Kim, Gina
    Filippou, Panagiota S.
    Sanchez, Luis Rivera
    Entenberg, David
    Marks, Douglas K.
    Oktay, Maja H.
    Karagiannis, George S.
    [J]. FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [3] Cellular biology of fracture healing
    Bahney, Chelsea S.
    Zondervan, Robert L.
    Allison, Patrick
    Theologis, Alekos
    Ashley, Jason W.
    Ahn, Jaimo
    Miclau, Theodore
    Marcucio, Ralph S.
    Hankenson, Kurt D.
    [J]. JOURNAL OF ORTHOPAEDIC RESEARCH, 2019, 37 (01) : 35 - 50
  • [4] Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer.
    Braun, S
    Pantel, K
    Muller, P
    Janni, W
    Hepp, F
    Kentenich, CRM
    Gastroph, S
    Wischnik, A
    Dimpfl, T
    Kindermann, G
    Riethmuller, G
    Schlimok, G
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (08) : 525 - 533
  • [5] Occult tumor cells in bone marrow of patients with locoregionally restricted ovarian cancer predict early distant metastatic relapse
    Braun, S
    Schindlbeck, C
    Hepp, F
    Janni, W
    Kentenich, C
    Reithmüller, G
    Pantel, K
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (02) : 368 - 375
  • [6] A pooled analysis of bone marrow micrometastasis in breast cancer
    Braun, S
    Vogl, FD
    Naume, B
    Janni, W
    Osborne, MP
    Coombes, RC
    Schlimok, G
    Diel, IJ
    Gerber, B
    Gebauer, G
    Pierga, JY
    Marth, C
    Oruzio, D
    Wiedswang, G
    Solomayer, EF
    Kundt, G
    Strobl, B
    Fehm, T
    Wong, GYC
    Bliss, J
    Vincent-Salomon, A
    Pantel, K
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (08) : 793 - 802
  • [7] Human Tumor-Associated Macrophage and Monocyte Transcriptional Landscapes Reveal Cancer-Specific Reprogramming, Biomarkers, and Therapeutic Targets
    Cassetta, Luca
    Fragkogianni, Stamatina
    Sims, Andrew H.
    Swierczak, Agnieszka
    Forrester, Lesley M.
    Zhang, Hui
    Soong, Daniel Y. H.
    Cotechini, Tiziana
    Anur, Pavane
    Lin, Elaine Y.
    Fidanza, Antonella
    Lopez-Yrigoyen, Martha
    Millar, Michael R.
    Urman, Alexandra
    Ai, Zhichao
    Spellman, Paul T.
    Hwang, E. Shelley
    Dixon, J. Michael
    Wiechmann, Lisa
    Coussens, Lisa M.
    Smith, Harriet O.
    Pollard, Jeffrey W.
    [J]. CANCER CELL, 2019, 35 (04) : 588 - +
  • [8] Metastatic niche functions and therapeutic opportunities
    Celia-Terrassa, Toni
    Kang, Yibin
    [J]. NATURE CELL BIOLOGY, 2018, 20 (08) : 868 - 877
  • [9] Centre for Cancer Registry Data at the Robert Koch Institute, DATA QUER EST INC PR, DOI [10.18444/5.03.01.0005.0015.0002, DOI 10.18444/5.03.01.0005.0015.0002]
  • [10] Breast cancer recurrence, bone metastases, and visceral metastases in women with stage II and III breast cancer in Denmark
    Cronin-Fenton, Deirdre
    Kjaersgaard, Anders
    Norgaard, Mette
    Amelio, Justyna
    Liede, Alexander
    Hernandez, Rohini K.
    Sorensen, Henrik T.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2018, 167 (02) : 517 - 528